REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [Contract Number]

Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material

and (ii) would likely cause competitive harm if publicly disclosed.

ADVANCE PURCHASE AGREEMENT ("APA")1

for the development, production, advance purchase and supply of a COVID-19 vaccine for EU Member States

NUMBER - SANTE/2020/C3/049

The European Commission (the "Commission"), acting on behalf and in the name of the Member States listed

in Annex I (the "participating Member State(s)")2

being represented for the purposes of the signature of this APA by Ms Stella Kyriakides, Commissioner for Health and Food

CUREVAC AG, Friedrich-Miescher-Str. 15, 72076 T bingen, Deutschland, HRB 754041, Stuttgart District Court,

represented for the purposes of the signature of this APA which has the form of a framework contract by [forename,

surname, function of legal representative],

The Commission, acting on behalf and in

the name of the participating Member States, and the contractor are together referred to as the "Parties"

and each individually as a "Party".

to the special conditions

and the general conditions of this APA and the following annexes:

which form an integral part

I. Special Conditions

If there is any conflict between different

provisions in this APA, the following rules must be applied:

All documents issued by the contractor

(such as end-user agreements, general terms and conditions, etc.) are held inapplicable, unless they are issued under or in accordance

with this APA (such as the final specifications, (formal) notifications, etc.). In all circumstances,

in the event of contradiction between this APA and documents issued by the contractor, this APA prevails,

regardless of any provision to the contrary in the contractor's documents.

For the purpose of this APA, the

following definitions (indicated in italics in the text) apply:

Additional Doses up-front payment':

the up-front payment relating to the Additional European Doses as specified in Article I.17.2(b).

Additional European Doses':

the additional number of doses, which may be ordered by the Commission in accordance with Article I.7.2.

company, partnership or other entity that controls, is controlled by, or is under common control with the contractor.

For purposes of this definition only, "control" means (a) to possess, directly or indirectly, the power to direct

the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting

rights or corporate governance or otherwise, or (b) to own, directly or indirectly, more than 50 % of the outstanding voting

securities or other ownership interest of such entity, provided that, if applicable law requires a minimum percentage of

local ownership, control will be established by direct or indirect beneficial ownership of 100 % of the maximum ownership

interest that may, under such applicable law, be owned by foreign interests, provided, however, that regarding the contractor,

the term affiliate shall not include [], [] and/or any other companies controlled by [] and/or [] that

are not subsidiaries of the contractor.

Apparent defect': any

defect of the Product existent at the moment of delivery at the delivery site of the relevant participating Member

State that has been identified or could have been identified upon visual inspection of the pallet or grouping box of the Product

or the temperature monitoring device. It may include a physical damage, a leakage, an incorrect labelling or temperature readings

or recordings that deviate from the required cold chain specifications.

Breach of obligations':

failure by the contractor to fulfil one or more of its contractual obligations, unless the APA (i) states explicitly

that the non-fulfilment of an obligation shall not result in any consequences or (ii) provides for a specific consequence other

than those set forth in Article II.14.

CMO': a contract manufacturing

Commission': the European

Confidential information or document':

any information or document disclosed or given between the Parties or on their behalf in the context of the negotiation

and conclusion of the APA (including the terms of the APA and the Vaccine Order Forms) and/or the performance

of the APA. It does not include any information (i) the receiving Party can prove was known to it prior to the date

of disclosure; (ii) the receiving Party can prove was lawfully obtained from a third party without any obligation of confidentiality;

(iii) is or becomes part of the public domain other than through any act or omission of the receiving Party; or (iv) is

independently developed by the receiving Party without use of or reference to the disclosing Party's confidential

information or documents, as evidenced by the receiving Party's records.

Conflict of interest':

a situation where the impartial and objective performance of this APA by the contractor is compromised for reasons

involving family, emotional life, political or national affinity, economic interest, any other direct or indirect personal interest,

or any other shared interest with the Commission, the participating Member State or any third party related to the

subject matter of this APA, it being understood that the conclusion, implementation and performance of further agreements

on the provision of the Product shall not constitute a conflict of interest.

Contractor': CUREVAC

AG with its seat in T bingen, registered with the commercial register of the local court of Stuttgart under HRB 754041.

the pandemic as further described in the Recitals.

the delivery site as indicated in the relevant Vaccine Order Form.

Dose': the amount of

the Product as specified in Article I.6.3.

EU marketing authorisation':

the approval under the relevant provisions of Regulation (EC) 726/2004 of the European Parliament and of the Council of 31 March

2004 laying down Union procedures for the authorisation and supervisions of medicinal products for human and veterinary use and

establishing a European Medicines Agency, by the European Commission necessary for the placing on the market of the Product

for vaccination in the territory of the European Union, including conditional marketing authorisation in accordance with Article

14-a of Regulation 726/2004 and Commission Regulation 507/2006/EC.

Final specification':

the final specification of the Product as to be determined by contractor in accordance with in Article I.6.2.

unforeseeable, exceptional situation or event beyond the control of the Parties that prevents either of them from fulfilling

any of their obligations under the APA. The situation or event must not be attributable to error or negligence on the part

of the Parties or on the part of the subcontractors and must prove to be inevitable despite their exercising due diligence.

Defaults of service, defects in equipment or material or delays in making them available, labour disputes, strikes and financial

difficulties may not be invoked as force majeure, unless they are caused by a relevant case of force majeure.

Formal notification' (or

formally notify'): form of communication between the Parties made in writing by mail or e-mail in English,

which provides the sender with compelling evidence that the message was delivered to the specified recipient.

Fraud': an act or omission

committed in order to make an unlawful gain for the perpetrator or another by causing a loss to the Union's financial interests,

and relating to: i) the use or presentation of false, incorrect or incomplete statements or documents, which has as its effect

the misappropriation or wrongful retention of funds or assets from the Union budget, ii) the non-disclosure of information in violation

of a specific obligation, with the same effect or iii) the misapplication of such funds or assets for purposes other than those

for which they were originally granted, which damages the Union's financial interests.

GDP': good distribution